Basic Information
| LncRNA/CircRNA Name | LINC00511 |
| Synonyms | NA |
| Region | GRCh38_17:72323123-72640472 |
| Ensemble | ENSG00000227036 |
| Refseq | NR_033876 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Western blot, Luciferase reporter assay, in vitro knockdown, etc. |
| Sample | breast cancer tissues, normal human breast epithelial cell (MCF-10A) and breast cancer cells (MDA-MB-468, MDA-MB-231, MDA-MB-453, MCF-7) |
| Expression Pattern | up-regulated |
| Function Description | LINC00511 was measured to be highly expressed in the breast cancer specimens and the high-expression was correlated with the poor prognosis. Functionally, the gain and loss-of-functional experiments revealed that LINC00511 promoted the proliferation, sphere-formation ability, stem factors (Oct4, Nanog, SOX2) expression and tumor growth in breast cancer cells. Mechanically, LINC00511 functioned as competing endogenous RNA (ceRNA) for miR-185-3p to positively recover E2F1 protein. Furthermore, transcription factor E2F1 bind with the promoter region of Nanog gene to promote it transcription. |
| Pubmed ID | 30482236 |
| Year | 2018 |
| Title | Long noncoding RNA LINC00511 contributes to breast cancer tumourigenesis and stemness by inducing the miR-185-3p/E2F1/Nanog axis |
External Links
| Links for LINC00511 | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |